Chuyển sang chế độ ngoại tuyến với ứng dụng Player FM !
Current Clinical Practice and NCCN Guidelines for CLL/SLL
Manage episode 429566073 series 3256997
In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:
- Prognostic variables when deciding between regimens
- Role of MRD in CLL
- Results from the phase II CAPTIVATE trial
- Choosing among the available covalent BTK inhibitors
- Preferred partner anti-CD20 antibody in CLL/SLL
- Role of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLL
- Use of CAR T-cell therapy in CLL/SLL
Presenters:
Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas
Jeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Shuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.
Link to full program:
https://bit.ly/3LzA2As
181 tập
Manage episode 429566073 series 3256997
In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:
- Prognostic variables when deciding between regimens
- Role of MRD in CLL
- Results from the phase II CAPTIVATE trial
- Choosing among the available covalent BTK inhibitors
- Preferred partner anti-CD20 antibody in CLL/SLL
- Role of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLL
- Use of CAR T-cell therapy in CLL/SLL
Presenters:
Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas
Jeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Shuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.
Link to full program:
https://bit.ly/3LzA2As
181 tập
ทุกตอน
×Chào mừng bạn đến với Player FM!
Player FM đang quét trang web để tìm các podcast chất lượng cao cho bạn thưởng thức ngay bây giờ. Đây là ứng dụng podcast tốt nhất và hoạt động trên Android, iPhone và web. Đăng ký để đồng bộ các theo dõi trên tất cả thiết bị.